Pentaglobin

DRUG2 trials

Sponsors

Gruppo Italiano Trapianto di Midollo Osseo, Medical University of Vienna

Conditions

COVID-19Septic Shock

Phase 2

Pentaglobin in CRE and PA Neutropenic Infections

Active, not recruitingNCT03494959

Gruppo Italiano Trapianto di Midollo OsseoSeptic Shock

Start: 2019-12-06End: 2025-05-31Target: 120Updated: 2025-01-06

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Medical University of ViennaCOVID-19

Start: 2020-04-16End: 2022-03-31Target: 500Updated: 2021-03-02

Related Papers

Visualizing a marker's degrees of necessity and of sufficiency in the predictiveness curve.

2025-04-23

Rivaroxaban to prevent major clinical outcomes in non-hospitalised patients with COVID-19: the CARE - COALITION VIII randomised clinical trial.

2023-05-1812 citations

Experiences and challenges faced by patients with COVID-19 who were hospitalised and participated in a randomised controlled trial: a qualitative study

BMJ Open2022-10-018 citations

Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)

Frontiers in Pharmacology2022-07-2215 citations

A Model Predicting Mortality of Hospitalized Covid-19 Patients Four Days After Admission: Development, Internal and Temporal-External Validation

Frontiers in Cellular and Infection Microbiology2022-01-2416 citations